For 10 years, NGR-TNF-α has been tested (both as a single agent and in combination with chemotherapy) in several phase I/II clinical trials in patients with advanced solid tumours (including melanoma, small cell lung cancer, colon, liver, and ovarian carcinomas) (reviewed in [8,167,169,173]). Here, RTN4R is linked to small cell lung carcinoma.